↓ Skip to main content

Pharmacological treatment of depression in patients with a primary brain tumour

Overview of attention for article published in Cochrane database of systematic reviews, May 2013
Altmetric Badge

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
22 Dimensions

Readers on

mendeley
74 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Pharmacological treatment of depression in patients with a primary brain tumour
Published in
Cochrane database of systematic reviews, May 2013
DOI 10.1002/14651858.cd006932.pub3
Pubmed ID
Authors

Alasdair G Rooney, Robin Grant

Abstract

This is an updated version of the original Cochrane review published in Issue 3, 2010.Patients with a primary brain tumour often experience depression, for which drug treatment may be prescribed. However, these patients are also at high risk of epileptic seizures, cognitive impairment and fatigue, all of which are potential side effects of antidepressants. The benefit, or harm, of pharmacological treatment of depression in brain tumour patients is unclear.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 74 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Spain 1 1%
United States 1 1%
Norway 1 1%
Unknown 71 96%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 13 18%
Student > Master 11 15%
Researcher 9 12%
Student > Doctoral Student 8 11%
Student > Postgraduate 7 9%
Other 26 35%
Readers by discipline Count As %
Medicine and Dentistry 31 42%
Psychology 11 15%
Nursing and Health Professions 9 12%
Unspecified 9 12%
Pharmacology, Toxicology and Pharmaceutical Science 4 5%
Other 10 14%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 31 May 2013.
All research outputs
#11,143,412
of 12,527,219 outputs
Outputs from Cochrane database of systematic reviews
#8,923
of 8,923 outputs
Outputs of similar age
#124,443
of 148,168 outputs
Outputs of similar age from Cochrane database of systematic reviews
#113
of 118 outputs
Altmetric has tracked 12,527,219 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 8,923 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 21.2. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 148,168 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 118 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.